{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:00:11Z","timestamp":1792807211644,"version":"4.5.0"},"reference-count":64,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2255495","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T07:06:09Z","timestamp":1694070369000},"page":"1155-1166","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective"],"prefix":"10.1080","volume":"26","author":[{"given":"Erin","family":"Johansson","sequence":"first","affiliation":[{"name":"Eli Lilly and Company Ltd, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Giovannitti","sequence":"additional","affiliation":[{"name":"Eli Lilly Italy S.p.A, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Mezzetti","sequence":"additional","affiliation":[{"name":"Eli Lilly Italy S.p.A, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-7879","authenticated-orcid":false,"given":"Na","family":"Lu","sequence":"additional","affiliation":[{"name":"Precision Statistics Consulting, Woodbury, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sabatino","sequence":"additional","affiliation":[{"name":"Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"#cr-split#-e_1_3_5_2_1.1","unstructured":"National Health Service. Symptoms: atopic eczema. 2019 Dec 5 [Internet]"},{"key":"#cr-split#-e_1_3_5_2_1.2","unstructured":"[cited 2022 Nov 22]. Available at https:\/\/www.nhs.uk\/conditions\/atopic-eczema\/symptoms\/."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.02.006"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5538"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.21.07129-2"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.07.008"},{"key":"e_1_3_5_8_1","unstructured":"National Institute for Health and Care Excellence (NICE). Single technology appraisal. Dupilumab for treating moderate to severe atopic dermatitis after topical treatments [ID1048] [Internet]; [cited 2022 Nov 22]. Committee Papers. Available at https:\/\/www.nice.org.uk\/guidance\/ta534\/documents\/committee-papers. Accessed 22 November 2022."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.19.06430-7"},{"key":"e_1_3_5_10_1","first-page":"750","article-title":"Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis","volume":"17","author":"Zimmermann M","year":"2018","unstructured":"Zimmermann M, Rind D, Chapman R, et\u00a0al. Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol. 2018;17(7):750\u2013756.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18429"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18345"},{"key":"#cr-split#-e_1_3_5_13_1.1","unstructured":"European Medicines Agency. Dupixent: authorisation details. 2017 Sep 26 [Last update: 2021 Jan 22"},{"key":"#cr-split#-e_1_3_5_13_1.2","unstructured":"cited 2022 Nov 22]. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent#authorisation-details-section."},{"key":"#cr-split#-e_1_3_5_14_1.1","unstructured":"European Medicines Agency. Protopic: authorisation Details. 2002 Feb 27 [Last update: 2020 Sep 7"},{"key":"#cr-split#-e_1_3_5_14_1.2","unstructured":"cited 2022 Nov 22]. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/protopic#authorisation-details-section."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JDN.0000000000000185"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14080"},{"key":"#cr-split#-e_1_3_5_18_1.1","unstructured":"European Medicines Agency. Olumiant: authorisation Details. 2017 Feb 13 [Last update: 2020 Dec 15"},{"key":"#cr-split#-e_1_3_5_18_1.2","unstructured":"cited 2022 Nov 22]. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant#authorisation-details-section."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21630"},{"key":"e_1_3_5_23_1","unstructured":"Italian Medicines Agency (AIFA). DUPIXENT (dupilumab) dermatite atopica (AD). 2022. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/www.aifa.gov.it\/documents\/20142\/1663139\/Scheda_Registro_DUPIXENT_08.03.2022.zip."},{"key":"e_1_3_5_24_1","unstructured":"Italian Medicines Agency (AIFA). Guidelines for the compilation of the dossier to support the reimbursability and price application of a medicine. Version 1 2020. [Internet]; [cited 2022 Nov 22] Available at https:\/\/www.aifa.gov.it\/documents\/20142\/1283800\/Linee_guida_dossier_domanda_rimborsabilita.pdf."},{"key":"e_1_3_5_25_1","unstructured":"Eli Lilly and Company Limited. Olumiant (baricitinib) 4\u2009mg film-coated tablets. Summary of product characteristics. [Internet]; [cited 2022 Nov 22] Available at https:\/\/www.medicines.org.uk\/emc\/product\/7486\/smpc#."},{"key":"e_1_3_5_26_1","unstructured":"Sanofi Genzyme. Dupixent (dupilumab) 300\u2009mg solution for injection in pre-filled pen. Summary of product characteristics. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/www.medicines.org.uk\/emc\/product\/11321\/smpc."},{"key":"e_1_3_5_27_1","unstructured":"National Institute for Health and Care Excellence (NICE). Dupilumab for treating moderate to severe atopic dermatitis after topical treatments. Technology appraisal guidance [TA534]. 1 August 2018. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/www.nice.org.uk\/guidance\/ta534."},{"key":"e_1_3_5_28_1","unstructured":"Papadia DG FARMACOECONOMIA e FARMACOEPIDEMIOLOGIA. Universit\u00e0 degli Studi di Trieste \u2013 Corsi di Studio in Farmacia Per gli studenti del Corso di Laurea in Farmacia ed in C.T.F. \u2013 versione aggiornata marzo 2018. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/moodle2.units.it\/pluginfile.php\/194171\/mod_resource\/content\/1\/farmeconepid.pdf. [Italian]"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00734-w"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(97)00049-8"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.07.026"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.02.031"},{"key":"e_1_3_5_34_1","unstructured":"I.Stat. Life tables. 2019. [Internet]; [cited 2022 Nov 22]. Available at http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_MORTALITA1#."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.04.008"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.10.029"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0201-6"},{"key":"e_1_3_5_39_1","unstructured":"Compendio Farmadati. 2020. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/www.farmadati.it\/. [Italian]"},{"key":"e_1_3_5_40_1","unstructured":"Information Hospital Service. 2021. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/www.infohospital.com\/en\/index.html."},{"key":"e_1_3_5_41_1","unstructured":"Gelmetti C Girolomoni G Patrizi A. revisione critica di linee guida e raccomandazioni pratiche per la gestione dei pazienti con dermatite atopica. [Internet]; [cited 2022 Nov 19]. Available at https:\/\/www.pacinimedicina.it\/wp-content\/uploads\/dermatite-atopica_sidemast.pdf. [Italian]"},{"key":"e_1_3_5_42_1","unstructured":"Gazzetta Ufficiale. 2013. 23. [Italian]"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.7175\/fe.v4i2.773"},{"key":"e_1_3_5_44_1","unstructured":"Ministry of Health. Pronto Soccorso e sistema 118 - Proposta metodologica per la valutazione dei costi dell\u2019emergenza. 2021. [Italian]"},{"key":"e_1_3_5_45_1","unstructured":"Nomenclatore Tariffario FASDAC. 2020."},{"key":"e_1_3_5_46_1","unstructured":"Sistema Socio Sanitario. Regione Lombardia ASST Spedali Civili. Psicologia. 2022. [Internet]; [cited 2022 Dec 8]. Available at https:\/\/www.asst-spedalicivili.it\/servizi\/Menu\/dinamica.aspx?idSezione=616&idArea=38147&idCat=40274&ID=45520&TipoElemento=categoria. [Italian]"},{"key":"e_1_3_5_47_1","unstructured":"Palmonella A. Gli psicologi penitenziari chiedono aiuto all\u2019ordine degli psicologi. [Internet]; [cited 2022 Dec 8]. Available at https:\/\/www.altrapsicologia.it\/articoli\/gli-psicologi-penitenziari-chiedono-aiuto-allordine-degli-psicologi-2\/?print=print. [Italian]"},{"key":"e_1_3_5_48_1","unstructured":"Tariffario FISDAF. 2016. [Italian]"},{"key":"e_1_3_5_49_1","unstructured":"Tariffario regionale per la remunerazione delle prestazioni di assistenza ospedaliera. 2017. [Internet]; [cited 2022 Dec 8]. Available at https:\/\/www.regione.sardegna.it\/documenti\/1_26_20171122122049.pdf. [Italian]"},{"key":"e_1_3_5_50_1","unstructured":"Decreto Commissario ad acta U00310\/13. Approvazione del tariffario regionale per la remunerazione delle prestazioni di assistenza ospedaliera D.M.18.10.12. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/www.asl.vt.it\/Staff\/SistemiInformativi\/Documentazione\/sio\/pdf\/Decr_U00310_04_07_2013.pdf. [Italian]"},{"key":"e_1_3_5_51_1","unstructured":"Institute for Clinical and Economic Review (ICER). Dupilumab and crisaborole for atopic dermatitis: effectiveness and value final evidence report and meeting summary. 8 June 2017. [Internet]; [cited 2022 Nov 22]. Available at https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/MWCEPAC_ATOPIC_FINAL_EVIDENCE_REPORT_060717.pdf."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1273"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.074"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta10460"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08436.x"},{"key":"#cr-split#-e_1_3_5_56_1.1","unstructured":"European Medicines Agency. Adtralza (tralokinumab): authorisation details. 2021 Jun 17. [Internet]"},{"key":"#cr-split#-e_1_3_5_56_1.2","unstructured":"[cited 2022 Nov 22]. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adtralza#authorisation-details-section."},{"key":"#cr-split#-e_1_3_5_57_1.1","unstructured":"European Medicines Agency. Cibinqo (abrocitinib): authorisation details. 2022 Oct 11. [Internet]"},{"key":"#cr-split#-e_1_3_5_57_1.2","unstructured":"[cited 2022 Nov 22]. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cibinqo#authorisation-details-section."},{"key":"#cr-split#-e_1_3_5_58_1.1","unstructured":"European Medicines Agency. Rinvoq (upadacitinib): authorisation details. 2022 Sep 22. [Internet]"},{"key":"#cr-split#-e_1_3_5_58_1.2","unstructured":"[cited 2022 Nov 22]. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq#authorisation-details-section."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2255495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T09:58:02Z","timestamp":1701943082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2255495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2255495"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2255495","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}